Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Third Avenue Small Cap Value Fund Matthew Fine, CFA and Jason Wolf, CFA | “Supernus Pharmaceuticals announced an opportunistic acquisition of Sage Therapeutics, which will be funded by Supernus' $460 million net cash balance. Sage is a company which makes the first and only F.D.A. approved treatment for postpartum depression and, itself, possesses net cash in excess of $420 million as of its most recent filing. BSD Analysis: Supernus Pharmaceuticals is a deep-value, specialized biopharma pure-play whose stock is an asymmetric recovery bet on the successful expansion of its Central Nervous System (CNS) franchise. The core thesis is driven by the successful launch and patent protection of Qelbree (non-stimulant ADHD treatment) and Trokendi XR. The company is defensively positioned, with 48% institutional ownership, signaling professional money's belief in the long-term value of its specialized portfolio. Despite a recent 18.4% stock dip, the underlying demand for its psychiatric and neurological drugs is non-cyclical. The stock is a leveraged play on successful pipeline expansion and the inherent value of its established CNS brands.” | BULL | Q2 2025 Jul 17, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
